Previous 10 | Next 10 |
STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chro...
Calliditas Therapeutics to participate in upcoming investor conferences PR Newswire STOCKHOLM , May 10, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its management te...
Calliditas Therapeutics' 2021 Annual Report Published PR Newswire STOCKHOLM , April 27, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the company's websi...
Travere Therapeutics (TVTX) is a US-based pharmaceutical company with a lead asset Sparsentan that targets rare kidney diseases (IgAN and FSGS). We do not think the FDA will approve Sparsentan due to the drug's inability to drive material eGFR benefit even though it demonstrated subst...
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2018/2022 PR Newswire STOCKHOLM , March 24, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO...
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...
Calliditas Therapeutics (NASDAQ:CALT) said its partner Everest Medicines plans to submit a new drug application (NDA) for kidney disease drug Nefecon in China in the H2 2022. The company said Everest received breakthrough therapy designation in China in December 2020, and have completed enrol...
Updated regulatory plans for NEFECON in China PR Newswire STOCKHOLM , March 18, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK) plans to sub...
Calliditas Therapeutics (NASDAQ:CALT) has expanded its licensing agreement with Everest Medicines II Limited to extend the territory covered to include South Korea for an upfront payment of $3M as well as additional payments and royalties related to future potential approvals and co...
Expansion of Everest Medicine's licence agreement to include South Korea PR Newswire STOCKHOLM , March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its l...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...